HIV-1 and HIV-2 Vif interact with human APOBEC3 proteins using completely different determinants

Journal of Virology

Volumn 88, Issue 17, 2014, Pages 9893-9908

  Smith, Jessica L ^a   Izumi, Taisuke ^a   Borbet, Timothy C ^a   Hagedorn, Ariel N ^a   Pathak, Vinay K ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOBEC3 PROTEIN, HUMAN; CYTOSINE DEAMINASE; PROTEIN BINDING; VIF PROTEIN; VIF PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1; VIF PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 2;

ANIMAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; METABOLISM; PHYSIOLOGY; PRIMATE; PROTEIN ANALYSIS;

ANIMALS; CYTOSINE DEAMINASE; HIV-1; HIV-2; HUMANS; PRIMATES; PROTEIN BINDING; PROTEIN INTERACTION MAPPING; VIF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS;

EID: 84921980261     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01318-14     Document Type: Article

References (73)

1. Harris RS, Bishop KN, Sheehy AM, Craig HM, Petersen-Mahrt SK, Watt IN, Neuberger MS, Malim MH. 2003. DNA deamination mediates innate immunity to retroviral infection. Cell 113:803-809. http://dx.doi.org/10.1016/S0092-8674(03)00423-9.
2. Lecossier D, Bouchonnet F, Clavel F, Hance AJ. 2003. Hypermutation of HIV-1 DNA in the absence of the Vif protein. Science 300:1112. http://dx.doi.org/10.1126/science.1083338.
3. Mangeat B, Turelli P, Caron G, Friedli M, Perrin L, Trono D. 2003. Broad antiretroviral defence by humanAPOBEC3Gthrough lethal editing of nascent reverse transcripts. Nature 424:99-103. http://dx.doi.org/10.1038/nature01709.
4. Suspene R, Sommer P, Henry M, Ferris S, Guetard D, Pochet S, Chester A, Navaratnam N, Wain-Hobson S, Vartanian JP. 2004. APOBEC3G is a single-stranded DNA cytidine deaminase and functions independently of HIV reverse transcriptase. Nucleic Acids Res. 32:2421-2429. http://dx.doi.org/10.1093/nar/gkh554.
5. Yu Q, Konig R, Pillai S, Chiles K, Kearney M, Palmer S, Richman D, Coffin JM, Landau NR. 2004. Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome. Nat. Struct. Mol. Biol. 11:435-442. http://dx.doi.org/10.1038/nsmb758.
6. Zhang H, Yang B, Pomerantz RJ, Zhang CM, Arunachalam SC, Gao L. 2003. The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature 424:94-98. http://dx.doi.org/10.1038/nature01707.
7. Izumi T, Shirakawa K, Takaori-Kondo A. 2008. Cytidine deaminases as a weapon against retroviruses and a new target for antiviral therapy. Mini Rev. Med. Chem. 8:231-238. http://dx.doi.org/10.2174/138955708783744047.
8. Izumi T, Burdick R, Shigemi M, Plisov S, Hu WS, Pathak VK. 2013. Mov10 and APOBEC3G localization to processing bodies is not required for virion incorporation and antiviral activity. J. Virol. 87:11047-11062. http://dx.doi.org/10.1128/JVI.02070-13.
9. Izumi T, Takaori-Kondo A, Shirakawa K, Higashitsuji H, Itoh K, Io K, Matsui M, Iwai K, Kondoh H, Sato T, Tomonaga M, Ikeda S, Akari H, Koyanagi Y, Fujita J, Uchiyama T. 2009. MDM2 is a novel E3 ligase for HIV-1 Vif. Retrovirology 6:1. http://dx.doi.org/10.1186/1742-4690-6-1.
10. Izumi T, Io K, Matsui M, Shirakawa K, Shinohara M, Nagai Y, Kawahara M, Kobayashi M, Kondoh H, Misawa N, Koyanagi Y, Uchiyama T, Takaori-Kondo A. 2010. HIV-1 viral infectivity factor interacts with TP53 to induce G2 cell cycle arrest and positively regulate viral replication. Proc. Natl. Acad. Sci. U. S. A. 107:20798-20803. http://dx.doi.org/10.1073/pnas.1008076107.
11. Letko M, Silvestri G, Hahn BH, Bibollet-Ruche F, Gokcumen O, Simon V, Ooms M. 2013. Vif proteins from diverse primate lentiviral lineages use the same binding site in APOBEC3G. J. Virol. 87:11861-11871. http://dx.doi.org/10.1128/JVI.01944-13.
12. Compton AA, Emerman M. 2013. Convergence and divergence in the evolution of the APOBEC3G-Vif interaction reveal ancient origins of simian immunodeficiency viruses. PLoS Pathog. 9:e1003135. http://dx.doi.org/10.1371/journal.ppat.1003135.
13. Compton AA, Malik HS, Emerman M. 2013. Host gene evolution traces the evolutionary history of ancient primate lentiviruses. Philos. Trans. R. Soc. Lond. B Biol. Sci. 368:20120496. http://dx.doi.org/10.1098/rstb.2012.0496.
14. Yu XH, Yu YK, Liu BD, Luo K, Kong W, Mao PY, Yu XF. 2003. Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 302:1056-1060. http://dx.doi.org/10.1126/science.1089591.
15. Kobayashi M, Takaori-Kondo A, Miyauchi Y, Iwai K, Uchiyama T. 2005. Ubiquitination of APOBEC3G by an HIV-1 Vif-Cullin5-Elongin B-Elongin C complex is essential for Vif function. J. Biol. Chem. 280: 18573-18578. http://dx.doi.org/10.1074/jbc.C500082200.
16. Shindo K, Takaori-Kondo A, Kobayashi M, Abudu A, Fukunaga K, Uchiyama T. 2003. The enzymatic activity of CEM15/Apobec-3G is essential for the regulation of the infectivity of HIV-1 virion but not a sole determinant of its antiviral activity. J. Biol. Chem. 278:44412-44416. http://dx.doi.org/10.1074/jbc.C300376200.
17. Marin M, Rose KM, Kozak SL, Kabat D. 2003. HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nat. Med. 9:1398-1403. http://dx.doi.org/10.1038/nm946.
18. Sheehy AM, Gaddis NC, Malim MH. 2003. The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat. Med. 9:1404-1407. http://dx.doi.org/10.1038/nm945.
19. Krupp A, McCarthy KR, Ooms M, Letko M, Morgan JS, Simon V, Johnson WE. 2013. APOBEC3G polymorphism as a selective barrier to cross-species transmission and emergence of pathogenic SIV and AIDS in a primate host. PLoS Pathog. 9:e1003641. http://dx.doi.org/10.1371/journal.ppat.1003641.
20. Bieniasz PD. 2004. Intrinsic immunity: a front-line defense against viral attack. Nat. Immunol. 5:1109-1115. http://dx.doi.org/10.1038/ni1125.
21. Yan N, Chen ZJJ. 2012. Intrinsic antiviral immunity. Nat. Immunol. 13:214-222. http://dx.doi.org/10.1038/ni.2229.
22. Kirmaier A, Wu F, Newman RM, Hall LR, Morgan JS, O'Connor S, Marx PA, Meythaler M, Goldstein S, Buckler-White A, Kaur A, Hirsch VM, Johnson WE. 2010. TRIM5 suppresses cross-species transmission of a primate immunodeficiency virus and selects for emergence of resistant variants in the new species. PLoS Biol. 8:e1000462. http://dx.doi.org/10.1371/journal.pbio.1000462.
23. Etienne L, Hahn BH, Sharp PM, Matsen FA, Emerman M. 2013. Gene loss and adaptation to hominids underlie the ancient origin of HIV-1. Cell Host Microbe 14:85-92. http://dx.doi.org/10.1016/j.chom.2013.06.002.
24. Sharp PM, Hahn BH. 2011. Origins of HIV and the AIDS pandemic. Cold Spring Harb. Perspect. Med. 1:a006841. http://dx.doi.org/10.1101/cshperspect.a006841.
25. Gaddis NC, Sheehy AM, Ahmad KM, Swanson CM, Bishop KN, Beer BE, Marx PA, Gao F, Bibollet-Ruche F, Hahn BH, Malim MH. 2004. Further investigation of simian immunodeficiency virus Vif function in human cells. J. Virol. 78:12041-12046. http://dx.doi.org/10.1128/JVI.78.21.12041-12046.2004.
26. Meyerson NR, Sawyer SL. 2011. Two-stepping through time: mammals and viruses. Trends Microbiol. 19:286-294. http://dx.doi.org/10.1016/j.tim.2011.03.006.
27. Patel MR, Emerman M, Malik HS. 2011. Paleovirology-ghosts and gifts of viruses past. Curr. Opin. Virol. 1:304-309. http://dx.doi.org/10.1016/j.coviro.2011.06.007.
28. Johnson WE. 2013. Rapid adversarial co-evolution of viruses and cellular restriction factors. Curr. Top. Microbiol. Immunol. 371:123-151. http://dx.doi.org/10.1007/978-3-642-37765-5_5.
29. Yu X, Yu Y, Liu B, Luo K, Kong W, Mao P, Yu XF. 2003. Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 302:1056-1060. http://dx.doi.org/10.1126/science.1089591.
30. Jager S, Cimermancic P, Gulbahce N, Johnson JR, McGovern KE, Clarke SC, Shales M, Mercenne G, Pache L, Li K, Hernandez H, Jang GM, Roth SL, Akiva E, Marlett J, Stephens M, D'Orso I, Fernandes J, Fahey M, Mahon C, O'Donoghue AJ, Todorovic A, Morris JH, Maltby DA, Alber T, Cagney G, Bushman FD, Young JA, Chanda SK, Sundquist WI, Kortemme T, Hernandez RD, Craik CS, Burlingame A, Sali A, Frankel AD, Krogan NJ. 2012. Global landscape of HIV-human protein complexes. Nature 481: 365-370. http://dx.doi.org/10.1038/nature10719.
31. Stanley DJ, Bartholomeeusen K, Crosby DC, Kim DY, Kwon E, Yen L, Cartozo NC, Li M, Jager S, Mason-Herr J, Hayashi F, Yokoyama S, Krogan NJ, Harris RS, Peterlin BM, Gross JD. 2012. Inhibition of a NEDD8 cascade restores restriction of HIV by APOBEC3G. PLoS Pathog. 8:e1003085. http://dx.doi.org/10.1371/journal.ppat.1003085.
32. Jager S, Kim DY, Hultquist JF, Shindo K, LaRue RS, Kwon E, Li M, Anderson BD, Yen L, Stanley D, Mahon C, Kane J, Franks-Skiba K, Cimermancic P, Burlingame A, Sali A, Craik CS, Harris RS, Gross JD, Krogan NJ. 2012. Vif hijacks CBF-beta to degrade APOBEC3G and promote HIV-1 infection. Nature 481:371-375. http://dx.doi.org/10.1038/nature10693.
33. Zhang W, Du J, Evans SL, Yu Y, Yu XF. 2012. T-cell differentiation factor CBF-beta regulates HIV-1 Vif-mediated evasion of host restriction. Nature 481:376-379. http://dx.doi.org/10.1038/nature10718.
34. Russell RA, Pathak VK. 2007. Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F. J. Virol. 81:8201-8210. http://dx.doi.org/10.1128/JVI.00395-07.
35. Binka M, Ooms M, Steward M, Simon V. 2012. The activity spectrum of Vif from multiple HIV-1 subtypes against APOBEC3G, APOBEC3F, and APOBEC3H. J. Virol. 86:49-59. http://dx.doi.org/10.1128/JVI.06082-11.
36. Simon V, Zennou V, Murray D, Huang Y, Ho DD, Bieniasz PD. 2005. Natural variation in Vif: differential impact on APOBEC3G/3F and a potential role in HIV-1 diversification. PLoS Pathog. 1:e6. http://dx.doi.org/10.1371/journal.ppat.0010006.
37. Chen G, He Z, Wang T, Xu R, Yu XF. 2009. A patch of positively charged amino acids surrounding the human immunodeficiency virus type 1 Vif SLVx4Yx9Y motif influences its interaction with APOBEC3G. J. Virol. 83:8674-8682. http://dx.doi.org/10.1128/JVI.00653-09.
38. He Z, Zhang W, Chen G, Xu R, Yu XF. 2008. Characterization of conserved motifs in HIV-1 Vif required for APOBEC3G and APOBEC3F interaction. J. Mol. Biol. 381:1000-1011. http://dx.doi.org/10.1016/j.jmb.2008.06.061.
39. Tian C, Yu X, Zhang W, Wang T, Xu R, Yu XF. 2006. Differential requirement for conserved tryptophans in human immunodeficiency virus type 1 Vif for the selective suppression of APOBEC3G and APOBEC3F. J. Virol. 80:3112-3115. http://dx.doi.org/10.1128/JVI.80.6.3112-3115.2006.
40. Russell RA, Smith J, Barr R, Bhattacharyya D, Pathak VK. 2009. Distinct domains within APOBEC3G and APOBEC3F interact with separate regions of human immunodeficiency virus type 1 Vif. J. Virol. 83: 1992-2003. http://dx.doi.org/10.1128/JVI.01621-08.
41. Chaipan C, Smith JL, Hu WS, Pathak VK. 2013. APOBEC3G restricts HIV-1 to a greater extent than APOBEC3F and APOBEC3DE in human primary CD4-T cells and macrophages. J. Virol. 87:444-453. http://dx.doi.org/10.1128/JVI.00676-12.
42. Smith JL, Pathak VK. 2010. Identification of specific determinants of human APOBEC3F, APOBEC3C, and APOBEC3DE and African green monkey APOBEC3F that interact with HIV-1 Vif. J. Virol. 84:12599-12608. http://dx.doi.org/10.1128/JVI.01437-10.
43. Doehle BP, Schafer A, Cullen BR. 2005. Human APOBEC3B is a potent inhibitor of HIV-1 infectivity and is resistant to HIV-1 Vif. Virology 339: 281-288. http://dx.doi.org/10.1016/j.virol.2005.06.005.
44. Nguyen KL, Llano M, Akari H, Miyagi E, Poeschla EM, Strebel K, Bour S. 2004. Codon optimization of the HIV-1 vpu and vif genes stabilizes their mRNA and allows for highly efficient Rev-independent expression. Virology 319:163-175. http://dx.doi.org/10.1016/j.virol.2003.11.021.
45. Xu HZ, Svarovskaia ES, Barr R, Zhang YJ, Khan MA, Strebel K, Pathak VK. 2004. A single amino acid substitution in human APOBEC3G anti-retroviral enzyme confers resistance to HIV-1 virion infectivity factorinduced depletion. Proc. Natl. Acad. Sci. U. S. A. 101:5652-5657. http://dx.doi.org/10.1073/pnas.0400830101.
46. Yang SL, Delgado R, King SR, Woffendin C, Barker CS, Yang ZY, Xu L, Nolan GP, Nabel GJ. 1999. Generation of retroviral vector for clinical studies using transient transfection. Hum. Gene Ther. 10:123-132. http://dx.doi.org/10.1089/10430349950019255.
47. Derdeyn CA, Decker JM, Sfakianos JN, Wu XY, O'Brien WA, Ratner L, Kappes JC, Shaw GM, Hunter E. 2000. Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J. Virol. 74:8358-8367. http://dx.doi.org/10.1128/JVI.74.18.8358-8367.2000.
48. Wei XP, Decker JM, Liu HM, Zhang Z, Arani RB, Kilby JM, Saag MS, Wu XY, Shaw GM, Kappes JC. 2002. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob. Agents Chemother. 46:1896-1905. http://dx.doi.org/10.1128/AAC.46.6.1896-1905.2002.
49. Burdick R, Smith JL, Chaipan C, Friew Y, Chen J, Venkatachari NJ, Delviks-Frankenberry KA, Hu WS, Pathak VK. 2010. P body-associated protein Mov10 inhibits HIV-1 replication at multiple stages. J. Virol. 84: 10241-10253. http://dx.doi.org/10.1128/JVI.00585-10.
50. Unutmaz D, KewalRamani VN, Marmon S, Littman DR. 1999. Cytokine signals are sufficient for HIV-1 infection of resting human T lymphocytes. J. Exp. Med. 189:1735-1746. http://dx.doi.org/10.1084/jem.189.11.1735.
51. Yee JK, Friedmann T, Burns JC. 1994. Generation of high-titer pseudotyped retroviral vectors with very broad-host-range. Methods Cell Biol. 43:99-112. http://dx.doi.org/10.1016/S0091-679X(08)60600-7.
52. Goncalves J, Jallepalli P, Gabuzda DH. 1994. Subcellular localization of the Vif protein of human immunodeficiency virus type 1. J. Virol. 68:704-712.
53. Refsland EW, Hultquist JF, Harris RS. 2012. Endogenous origins of HIV-1 G-to-A hypermutation and restriction in the nonpermissive T cell line CEM2n. PLoS Pathog. 8:e1002800. http://dx.doi.org/10.1371/journal.ppat.1002800.
54. Miyagi E, Brown CR, Opi S, Khan M, Goila-Gaur R, Kao S, Walker RC, Jr, Hirsch V, Strebel K. 2010. Stably expressed APOBEC3F has negligible antiviral activity. J. Virol. 84:11067-11075. http://dx.doi.org/10.1128/JVI.01249-10.
55. Schrofelbauer B, Chen D, Landau NR. 2004. A single amino acid of APOBEC3G controls its species-specific interaction with virion infectivity factor (Vif). Proc. Natl. Acad. Sci. U. S. A. 101:3927-3932. http://dx.doi.org/10.1073/pnas.0307132101.
56. Mangeat B, Turelli P, Liao S, Trono D. 2004. A single amino acid determinant governs the species-specific sensitivity of APOBEC3G to Vif action. J. Biol. Chem. 279:14481-14483. http://dx.doi.org/10.1074/jbc.C400060200.
57. Bogerd HP, Doehle BP, Wiegand HL, Cullen BR. 2004. A single amino acid difference in the host APOBEC3G protein controls the primate species specificity of HIV type 1 virion infectivity factor. Proc. Natl. Acad. Sci. U. S. A. 101:3770-3774. http://dx.doi.org/10.1073/pnas.0307713101.
58. Albin JS, LaRue RS, Weaver JA, Brown WL, Shindo K, Harjes E, Matsuo H, Harris RS. 2010. A single amino acid in human APOBEC3F alters susceptibility to HIV-1 Vif. J. Biol. Chem. 285:40785-40792. http://dx.doi.org/10.1074/jbc.M110.173161.
59. Bach D, Peddi S, Mangeat B, Lakkaraju A, Strub K, Trono D. 2008. Characterization of APOBEC3G binding to 7SL RNA. Retrovirology 5:54. http://dx.doi.org/10.1186/1742-4690-5-54.
60. Wang T, Tian C, Zhang W, Luo K, Sarkis PT, Yu L, Liu B, Yu Y, Yu XF. 2007. 7SL RNA mediates virion packaging of the antiviral cytidine deaminase APOBEC3G. J. Virol. 81:13112-13124. http://dx.doi.org/10.1128/JVI.00892-07.
61. Huthoff H, Autore F, Gallois-Montbrun S, Fraternali F, Malim MH. 2009. RNA-dependent oligomerization of APOBEC3G is required for restriction of HIV-1. PLoS Pathog. 5:e1000330. http://dx.doi.org/10.1371/journal.ppat.1000330.
62. Arnold K, Bordoli L, Kopp J, Schwede T. 2006. The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling. Bioinformatics 22:195-201. http://dx.doi.org/10.1093/bioinformatics/bti770.
63. Kiefer F, Arnold K, Kunzli M, Bordoli L, Schwede T. 2009. The SWISSMODEL repository and associated resources. Nucleic Acids Res. 37: D387-D392. http://dx.doi.org/10.1093/nar/gkn750.
64. Peitsch MC, Wells TN, Stampf DR, Sussman JL. 1995. The Swiss-3DImage collection and PDB-Browser on the World-Wide Web. Trends Biochem. Sci. 20:82-84. http://dx.doi.org/10.1016/S0968-0004(00)88963-X.
65. Russell RA, Moore MD, Hu WS, Pathak VK. 2009. APOBEC3G induces a hypermutation gradient: purifying selection at multiple steps during HIV-1 replication results in levels of G-to-A mutations that are high in DNA, intermediate in cellular viral RNA, and low in virion RNA. Retrovirology 6:16. http://dx.doi.org/10.1186/1742-4690-6-16.
66. Refsland EW, Stenglein MD, Shindo K, Albin JS, Brown WL, Harris RS. 2010. Quantitative profiling of the full APOBEC3 mRNA repertoire in lymphocytes and tissues: implications for HIV-1 restriction. Nucleic Acids Res. 38:4274-4284. http://dx.doi.org/10.1093/nar/gkq174.
67. Koning FA, Newman EN, Kim EY, Kunstman KJ, Wolinsky SM, Malim MH. 2009. Defining APOBEC3 expression patterns in human tissues and hematopoietic cell subsets. J. Virol. 83:9474-9485. http://dx.doi.org/10.1128/JVI.01089-09.
68. Gillick K, Pollpeter D, Phalora P, Kim EY, Wolinsky SM, Malim MH. 2013. Suppression of HIV-1 infection by APOBEC3 proteins in primary human CD4(-) T cells is associated with inhibition of processive reverse transcription as well as excessive cytidine deamination. J. Virol. 87:1508-1517. http://dx.doi.org/10.1128/JVI.02587-12.
69. Duggal NK, Fu W, Akey JM, Emerman M. 2013. Identification and antiviral activity of common polymorphisms in the APOBEC3 locus in human populations. Virology 443:329-337. http://dx.doi.org/10.1016/j.virol.2013.05.016.
70. Duggal NK, Malik HS, Emerman M. 2011. The breadth of antiviral activity of Apobec3DE in chimpanzees has been driven by positive selection. J. Virol. 85:11361-11371. http://dx.doi.org/10.1128/JVI.05046-11.
71. Virgen CA, Hatziioannou T. 2007. Antiretroviral activity and Vif sensitivity of rhesus macaque APOBEC3 proteins. J. Virol. 81:13932-13937. http://dx.doi.org/10.1128/JVI.01760-07.
72. Ooms M, Letko M, Binka M, Simon V. 2013. The resistance of human APOBEC3H to HIV-1 NL4-3 molecular clone is determined by a single amino acid in Vif. PLoS One 8:e57744. http://dx.doi.org/10.1371/journal.pone.0057744.
73. Kitamura S, Ode H, Nakashima M, Imahashi M, Naganawa Y, Kurosawa T, Yokomaku Y, Yamane T, Watanabe N, Suzuki A, Sugiura W, Iwatani Y. 2012. The APOBEC3C crystal structure and the interface for HIV-1 Vif binding. Nat. Struct. Mol. Biol. 19:1005-1010. http://dx.doi.org/10.1038/nsmb.2378.